Physician profile
Mark R Scanlan
NPI 1013933274
$4,399.89
in general payments reported to CMS, 2019-2025
16 companies · $800 in 2025
The $800 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $213 · 2021: $204 · 2022: $1,507 · 2023: $628 · 2024: $866 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,245.30 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,449.23 | 2022-2025 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $718.84 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $621.53 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $398.46 | 2019-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $289.32 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $264.18 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $232.90 | 2020-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $126.49 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $59.43 | 2021-2023 | Qelbree |
| Allergan, INC. | $58.09 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $57.41 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $41.79 | 2023-2025 | Auvelity |
| Lundbeck LLC | $25.51 | 2025 | Rexulti |
| Alfasigma USA, INC. | $22.55 | 2020 | |
| Idorsia Pharmaceuticals US INC | $19.34 | 2025 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Scanlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.